Company name: SciCann Therapeutics
Description: Developer of cannabis and cannabinoid based therapeutics products designed to target and modulate the endocannabinoid system. The company is dedicated to the discovery and development of novel and proprietary technologies in the cannabinoid space, including new therapeutic agents, drug candidates, novel cannabis genetics and personalized treatment tools.
Year founded: 2017
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
Start up capital raised (USD Million):
Business status: Product Development
Ownership: Privately Held (backing)
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Earnings before interest, tax, depreciation and amortization (EBITDA):
Financing Status: FV Pharma, a subsidiary of FSD Pharma (CSE: HUGE) reached definitive agreement to acquire a 15% stake in the company for $3 million on May 28, 2018, putting the company’s valuation at $20 million. FV Pharma will receive an exclusive license in Canada for the production and distribution of a line of proprietary cannabinoid-based, patent pending and indication-specific products developed by the company. Previously, the company raised venture funding from ThreeD Capital on an undisclosed date.
Number of active investors:
Profile last updated: 08-Sep-2018
Last known valuation: 20.00
Last known valuation date: 28-May-2018